Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
General7 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General9 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General10 hours agoAlbanese beats drum on economy as trade clouds gather
-
Business7 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher